Interaction between synthetic amyloid-beta-peptide (1-40) and its aggregation inhibitors studied by electrospray ionization mass spectrometry.

It is generally postulated that amyloid-beta-peptides play a central role in the progressive neurodegeneration observed in Alzheimer's disease. Important pathological properties of these peptides, such as neurotoxicity and resistance to proteolytic degradation, depend on the ability of amyloid-beta-peptides to form beta-sheet structures and/or amyloid fibrils. Amyloid-beta-peptides are known to aggregate spontaneously in vitro with the formation of amyloid fibrils. The intervention on the amyloid-beta-peptides aggregation process can be envisaged as an approach to stopping or slowing the progression of Alzheimer's disease. In the last few years a number of small molecules have been reported to interfere with the in vitro aggregation of amyloid-beta-peptides. Melatonin, a hormone recently found to protect neurons against amyloid-beta-peptide toxicity, interacts with amyloid-beta-peptide (1-40) and amyloid-beta-peptide (1-42) and inhibits the progressive formation of beta-sheet and/or amyloid fibrils. These interactions between melatonin and the amyloid peptides have been demonstrated by circular dichroism (CD) and electron microscopy for amyloid-beta-peptide (1-40) and amyloid-beta-peptide (1-42) and by nuclear magnetic resonance (NMR) spectroscopy for amyloid-beta-peptide (1-40). Our electrospray ionization mass spectrometric (ESI-MS) studies also proved that there is a hydrophobic interaction between amyloid-beta-peptide (1-40) and melatonin and the proteolytic investigations suggested that the interaction took place on the 29-40 amyloid-beta-peptide segment. The wide-ranging application of these results would provide further information and help in biological research.

[1]  C. Barrow,et al.  Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition. , 1991, Science.

[2]  R. Wetzel,et al.  Abeta amyloid fibrils possess a core structure highly resistant to hydrogen exchange. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Xiongfong Chen,et al.  Simultaneous assessment of conformation and aggregation of β‐amyloid peptide using electrospray ionization mass spectrometry , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  D. Kirschner,et al.  Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. , 1990, Science.

[5]  T. Holzman,et al.  Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. , 1994, Biophysical journal.

[6]  C. Barrow,et al.  On-line high-performance liquid chromatography/mass spectrometric investigation of amyloid-beta peptide variants found in Alzheimer's disease. , 1999, Rapid communications in mass spectrometry : RCM.

[7]  G. Fasman,et al.  Analysis of the circular dichroism spectrum of proteins using the convex constraint algorithm: a practical guide. , 1992, Analytical biochemistry.

[8]  D. Wemmer,et al.  Use of nuclear magnetic resonance in probing ligand-macromolecule interactions. , 1994, Methods in enzymology.

[9]  G. Glenner,et al.  Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .

[10]  P. Lansbury,et al.  The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. , 1993, Biochemistry.

[11]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P. Camilleri,et al.  β‐Cyclodextrin interacts with the Alzheimer amyloid β‐A4 peptide , 1994 .

[13]  R. Beavis,et al.  Fibrillogenesis of synthetic amyloid-β peptides is dependent on their initial secondary structure , 1995, Neuroscience Letters.

[14]  C. Soto,et al.  Inhibition of Alzheimer β-Fibrillogenesis by Melatonin* , 1998, The Journal of Biological Chemistry.

[15]  R. Reiter,et al.  Melatonin Prevents Death of Neuroblastoma Cells Exposed to the Alzheimer Amyloid Peptide , 1997, The Journal of Neuroscience.

[16]  T. Bandiera,et al.  Inhibitors of Aβ Peptide Aggregation as Potential anti-Alzheimer Agents , 1997 .

[17]  J. Seelig,et al.  Self-association of beta-amyloid peptide (1-40) in solution and binding to lipid membranes. , 1995, Journal of molecular biology.

[18]  C. Barrow,et al.  NMR studies of amyloid beta-peptides: proton assignments, secondary structure, and mechanism of an alpha-helix----beta-sheet conversion for a homologous, 28-residue, N-terminal fragment. , 1992, Biochemistry.

[19]  D. Butterfield,et al.  Direct evidence of oxidative injury produced by the Alzheimer's β-Amyloid peptide (1–40) in cultured hippocampal neurons , 1995, Experimental Neurology.

[20]  C. Barrow,et al.  Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. , 1992, Journal of molecular biology.

[21]  J. Reed,et al.  Aggregation and secondary structure of synthetic amyloid βA4 peptides of Alzheimer's disease , 1991 .